{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.7","value":"5.6"},{"groupId":"OG001","spread":"2.3","value":"5.7"},{"groupId":"OG002","spread":"1.9","value":"5.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"85"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.2","value":"-2.7"},{"groupId":"OG001","spread":"3.1","value":"-3.0"},{"groupId":"OG002","spread":"2.5","value":"-2.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"51"}],"units":"Participants"}],"title":"Week 25"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.9","value":"-3.5"},{"groupId":"OG001","spread":"2.8","value":"-2.2"},{"groupId":"OG002","spread":"2.3","value":"-3.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"32"}],"units":"Participants"}],"title":"Week 49"}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"91"}],"units":"Participants"}],"description":"The Worst Stiffness Numeric Rating Scale (NRS) was a 1-item, self-administered questionnaire assessing the \"worst\" stiffness in the last 24 hours. The NRS for this item ranged from 0 (no stiffness) to 10 (stiffness as bad as you can imagine).","dispersionType":"Standard Deviation","groups":[{"description":"Participants received treatment of Pexidartinib,1000 mg (5 capsules per day) for 2 weeks, then 800 mg (4 capsules per day) for 22 weeks and also received Pexidartinib in Part 2 at their prescribed dose.\n\nPexidartinib: Each capsule contains 200 mg of Pexidartinib for oral administration.","id":"OG000","title":"Pexidartinib Part 1 and Part 2"},{"description":"Participants received treatment of matching placebo (5 capsules per day) for 2 weeks, then matching placebo (4 capsules per day) for 22 weeks in Part 1 and also received Pexidartinib in Part 2 at their prescribed dose.\n\nPlacebo: Placebo capsule matching Pexidartinib capsule for oral administration Pexidartinib: Each capsule contains 200 mg of Pexidartinib for oral administration.","id":"OG001","title":"Placebo Part 1, Pexidartinib Part 2"},{"description":"All participants who received Pexidartinib in Part 1 and Part 2 as well as those who only received Pexidartinib in Part 2.","id":"OG002","title":"All Pexidartinib Treated"}],"paramType":"MEAN","populationDescription":"Worst stiffness was assessed in the ITT population, specifically among the Pexidartinib Part 1, Pexidartinib Part 2; Placebo Part 1, Pexidartinib Part 2; and All Pexidartinib Treated participants. Participants who received Placebo Part 1 only or Pexidartinib Part 2 only were not analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 25, and Week 49","title":"Mean Change From Baseline for Worst Stiffness Numeric Rating Scale Score (NRS) in Participants Receiving Pexidartinib Compared With Those on Placebo by Week 49","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"units on a scale"}